Ajanta Pharma Ltd (BSE: 532331, NSE: AJANTPHARM) — Business Report / Investor Feed

Business & Distribution Evaluation — Ajanta Pharma Ltd (BSE: 532331)

1. Business Identity

Ajanta Pharma Ltd is a specialty pharmaceutical formulation company focused on branded generics across India, Asia, and Africa, with a US generics business and an institutional (aid-agency) business in Africa [3][4]. The company operates exclusively in one reportable segment: "Pharmaceuticals and related products" [1][10].

Corporate Structure [Q3 FY26]:

2. Revenue Architecture

Revenue Model: Product sales of pharmaceutical formulations — branded generics (India, Asia, Africa), US generics, and institutional/tender-based sales to aid agencies in Africa [4][12].

Consolidated Revenue Trajectory

*Adjusted EBITDA (excl. ₹61 cr. mark-to-market forex loss) was ₹1,123 cr. at 28% margin [9M FY26] [14].

Full-year reference [FY25]: Revenue ₹4,648 cr., EBITDA ₹1,260 cr. (27%), PAT ₹920 cr. (20%) [3].

Multi-year CAGR: 3-year revenue CAGR of 11% and PAT CAGR of 25% [3][12]; 5-year revenue CAGR of 13% and PAT CAGR of 15% [4].

Return ratios [9M FY26]: ROCE 34%, RONW 26% [14]. Prior period [9M FY25]: ROCE 35%, RONW 26% [5].

Revenue Mix by Geography (₹ cr.)

Source: [12]

US Generics has shifted from a supplementary business to the primary growth engine — contributing 26% of 9M FY26 revenue at 46% YoY growth, while the legacy branded generics franchise grew only 9%. This concentration of incremental revenue in the US carries both pricing and regulatory risk.

Revenue mix commentary [9M FY26]:

• Branded Generics contribute ~71% of revenue, with India being the single largest geography (~31%) [12].
• US Generics has emerged as a significant growth driver at ~26% of revenue, growing 46% YoY [12].
• Africa Institution business is tender/agency-driven and volatile — declined 37% in 9M FY25 [4], partially recovered in 9M FY26 (+22% in Q3 but -6% for 9M) [12].

Customer type: Predominantly B2B (distributors, stockists, hospitals, aid agencies) with branded prescription sales through doctors/MRs. US business is generic (B2B to pharmacies/wholesalers). Africa Institution is B2G (government/aid agency procurement) [4][15].

Cost Structure Snapshot [Q3 FY25]

Source: [15]. Prior year Q3 FY24: COGS was 27% of revenue, indicating significant gross margin expansion.

COGS declining from 27% to 22% of revenue (Q3 FY24 → Q3 FY25) signals a meaningful mix shift toward higher-margin products — likely driven by the growing US generics contribution where Ajanta plays selectively in less-competitive niches.

Forex exposure: Significant — forex gains/losses are material line items. [FY25] full-year forex gain ₹32.96 cr. and forex loss ₹8.82 cr. (standalone) [10]. [9M FY26] consolidated: forex gain ₹52.80 cr., forex loss ₹61.34 cr. [2].

3. Product & Service Portfolio

Core Portfolio

India Branded Generics — Therapy-wise Performance [IQVIA MAT Dec 2025]

Source: [12]. Ajanta's India growth exceeded IPM by 28%, driven by volumes (+47% vs IPM) and new launches (+59% vs IPM) [12].

While Ajanta outpaces IPM overall (+11% vs +9%), it is notably underperforming in Cardiology (5% vs 13% IPM) — its largest therapy. Growth is being carried by Ophthalmology and Dermatology, suggesting the India growth story depends on these newer therapy pushes sustaining momentum.

India brand concentration [IQVIA MAT Dec 2025]: Top 10 brands contribute 53% of India revenue; brands of ₹25+ cr. scale [11]. 16 new launches in 9M FY26 including 1 first-to-market [11].

US Generics Pipeline [9M FY26]

Prior period [9M FY25]: 5 ANDA final approvals received, 4 filed; 48 commercialized out of 51 total approvals; 21 awaiting approval [4].

Recent Pipeline / Licensing

Semaglutide in-licensing (Dec 2025): Ajanta signed an in-licensing agreement with Biocon Ltd. for Semaglutide (GLP-1 receptor agonist) — exclusive marketing in 23 countries and semi-exclusive in 3 countries across Africa, Middle East, and Central Asia [3]. Product patent expires in most markets in March 2026; commercialization expected late 2026 or early 2027 after regulatory approvals [3].

R&D Investment

Source: [11][12]. Consistent at 5% of revenue across periods.

4. Value Chain Position

Position: Ajanta operates as an integrated pharmaceutical formulation company — spanning R&D → manufacturing → brand ownership → marketing & distribution [3].

Manufacturing Locations:

• Paithan, Maharashtra (Tablets, Capsules & Powder) [11][15]
• Guwahati, Assam (Tablets, Capsules, Ointments & Sterile Eye Drops) [15]
• Dahej, Gujarat [11]
• Pithampur, Madhya Pradesh (Tablets & Capsules) [11][15]

(3 additional facilities not individually identified in the filings reviewed)

Integration direction: Primarily forward-integrated — from manufacturing through to branded marketing with own field force. The Biocon Semaglutide deal represents backward in-licensing (sourcing finished product from Biocon for marketing) [3].

Key differentiators:

• Strong formulation capabilities [6][15]
• Ability to identify marketplace gaps, secure regulatory approvals, and launch differentiated products that scale into leadership brands [3]
• First-to-market positioning (50% of portfolio) [6][7]

Supplier/Sourcing data: Not disclosed in filings reviewed. Purchases of stock-in-trade (₹169.62 cr. for 9M FY25 consolidated [8]) indicate some third-party sourcing, though the majority is in-house manufacturing (cost of materials consumed: ₹655.64 cr. for 9M FY25 [8]).

5. Distribution Architecture

Channel Structure

Ajanta employs a direct field-force-driven distribution model for its branded generics business, with own Medical Representatives (MRs) on the ground in 30+ countries [3].

Pharma-Specific Distribution Metrics

MR growth trajectory: The field force expanded from 5,400+ [FY25 presentation, [6]] to 5,980+ [FY26 presentation, [7]], representing ~11% growth in field force size.

Geographic Distribution Reach

• Emerging Markets: Among Top 5 players in major markets across Africa, South-East Asia, Middle East & Central Asia [11][15]
• Distribution strategy: Expanding product portfolio, growing field size, building leadership in therapeutic/sub-therapeutic segments; also strengthening countries of small presence [15]
• Pipeline: Healthy product registrations pipeline supports continued geographic and therapeutic expansion [15]

Distribution Moat

• Deep commercial reach across Africa, Middle East, and Central Asia described as providing "an efficient and scalable pathway to accelerate market access" — evidenced by the Semaglutide in-licensing deal leveraging this existing infrastructure [3]
• Relationship depth: Many brands hold leadership positions in sub-therapeutic segments, built over years of on-ground presence [3]
• Time to replicate: Building own field force in 30+ countries with regulatory approvals and brand recognition represents a significant time and capital barrier
• Institutional channel (Africa): Subject to procurement volatility — sales declined 61% QoQ in Q3 FY25 and 37% for 9M FY25 due to lower agency procurement [4]; partial recovery in Q3 FY26 [12]

The Semaglutide in-licensing deal is a strategic validation of Ajanta's emerging market distribution moat — Biocon chose Ajanta specifically for its on-ground presence in 23+ countries. This asset-light model (in-license product, deploy existing field force) could become a repeatable template for high-value molecule partnerships.

Digital Distribution

Not disclosed in any filings reviewed. This is a notable gap given the pharma sector's increasing digital adoption.

Channel Economics

Specific channel margins, credit terms, incentive structures, and channel financing details are not disclosed in the filings reviewed.

6. Customer Profile

Customer Segments with Revenue Share [9M FY26]

Source: [12]

Customer Concentration

• Africa Institution business is concentrated on a few procurement agencies (aid agencies), making it inherently lumpy and volatile [4][15]
• Individual customer concentration metrics (top 1/5/10 customer %) are not disclosed
• The branded generics model inherently diversifies across thousands of prescribing doctors and dispensing pharmacies

Acquisition Model

• Branded Generics (India & Emerging Markets): Field sales via MR force detailing to doctors → prescription-driven pull through pharmacies/stockists [3]
• US Generics: ANDA-based regulatory approval → commercial launch to wholesalers/pharmacies; selective product strategy [6]
• Africa Institution: Tender/procurement driven by international aid agencies [4]

Key Data Gaps